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Edited by Gerrit van MeerAbstract The most common cystic ﬁbrosis-causing mutation is
the deletion of the widely conserved phenylalanine 508 (DF508)
of CFTR. The mutant is unable to fold correctly and to transit
to the plasma membrane. MRP1 belongs to the same subfamily
of ABC proteins as CFTR and confers resistance to a wide range
of chemotherapeutic drugs. By analogy, phenylalanine 728 was
deleted in MRP1. Our results shown that MRPDF728 is cor-
rectly targeted to the plasma membrane, actively transports
doxorubicin (DOX) and vincristine (VCR) and shares a structure
identical to MRP1. Intracellular GSH depletion however results
in a mistargeted mutant that is retained into the cytoplasm, while
in the same conditions wild-type MRP1 is correctly routed to the
plasma membrane. The GSH-protein complex could adopt a sta-
ble conformation protected against proteolytic degradation and
correctly targeted to the plasma membrane.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Cystic ﬁbrosis transmembrane conductance regulator
(CFTR) is a membrane chloride channel located in the apical
membrane of many chloride secreting and reabsorbing epithe-
lial cells [1]. This protein belongs to the ABCC subfamily of
the ATP-binding cassette transporter superfamily ABC. It is
composed of two nucleotide-binding domains (NBD1 and
NBD2) and two transmembrane domains (TMD1 and
TMD2), each spanning the membrane six times. CFTR also
contains a large cytosolic regulatory (R) domain between
NBD1 and TMD2, which is the site of regulatory phosphory-
lation [2]. A mutation (DF508) located in the center of the
NBD1 domain of CFTR (42 amino acids after the Walker AAbbreviations: ABC, ATP binding cassette; ATP, adenosine-50-tri-
phosphate; ATR, attenuated total reﬂection; BSO, DL-buthionine-
[S,R]-sulfoximine; CFTR, cystic ﬁbrosis conductance regulator;
DMSO, dimethyl sulfoxide; DOX, doxorubicin; FTIR, Fourier trans-
form infrared spectroscopy; GSH, glutathione; H/D, hydrogen/deute-
rium; HEK, human embryonic kidney; LTC4, leukotrienes C4; MDR,
multidrug resistance; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide; MRP, multidrug resistance protein; NBD, nuc-
leotide binding domain; PCR, polymerase chain reaction; Pgp, P-gly-
coprotein; TMD, transmembrane domain; VCR, vincristine
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responsible for a disease called cystic ﬁbrosis (CF) [1]. This
mutation causes a misfolding of the protein that is not targeted
correctly to the apical membrane but is retained in the endo-
plasmic reticulum (ER) in an inactive form that is rapidly
degraded [4–6].
Susan Cole and Roger Deeley discovered multidrug resis-
tance-associated Protein 1 (MRP1) in 1992 [3]. This membrane
protein belongs to the same ABCC subfamily of membrane
transporters as CFTR [46]. It confers resistance to a wide
range of chemotherapeutic drugs including anthracyclines, vin-
ca alkaloids and epipodophyllotoxins by rejecting them out of
the cells [7–9]. This transport mechanism requires ATP binding
and hydrolysis and for these drugs, the presence of GSH [10–
13]. MRP1 is an ATP-dependent transporter of anionic
compounds such as LTC4, methotrexate or glutathione-, sul-
fate- and glucoronide-conjugated organic anions. The trans-
port of such compounds is GSH-independent [14–16]. GSH
itself also is a MRP1 substrate. Drug binding to MRP1 occurs
through interactions with transmembrane domains [17–19]
while NBDs are responsible for ATP binding and hydrolysis
and for coupling energy release to substrate transport.
As CFTR, MRP1 is constituted of a typical ABC structure
core containing two nucleotide-binding domains (NBD1 and
NBD2) and two transmembrane domains (TMD1 and
TMD2), each spanning the membrane six times. MRP1 con-
tains an additional membrane domain spanning the membrane
ﬁve times (TMD0) and linked to the N-terminal TMD1 do-
main by a cytoplasmic loop L0 [1,20,21]. The role of this addi-
tional domain is for the moment not understood.
In this study, we analyzed the eﬀect of the deletion of phenyl-
alanine at position F728 in MRP1. This residue is located
exactly at the same position in MRP1 as F508 in CFTR with
respect to the Walker sites, in a sequence conserved among
the MRP subfamily (Fig. 1). Unlike CFTRDF508, MRPDF728
is correctly targeted to the plasma membrane and transports
MRP1 substrates. However, intracellular GSH depletion leads
to an intracellular localization of the mutant.2. Materials and methods
2.1. Materials
Antiproteases (Complete EDTA-free) were purchased from Roche
Diagnostics; Talon cobalt aﬃnity resin from Clontech; QuikChange
XLe site-directed mutagenesis kit from Stratagene; primary mouse
monoclonal antibody MRPm6 from Chemicon International; ECL
Plus Western Blotting detection reagent from Amersham Biosciences;
propidium iodide and Alexa Fluor 488 from Molecular Probes;
MTT reagent and BSO from Sigma; MicroSpin G-25 column from
Amersham Pharmacia Biotech. Plasmid pRC/CMV-MRP1 (wild-type)ation of European Biochemical Societies.
*
MRP1 : 674 VAVVGQVGCGKSSLLSALLAEMDKVEGHVAIKGS-------------VAYVPQQAWIQNDSLRENILFG-C
MRP2 : 667 VAVIGPVGSGKSSLISAMLGEMENVHGHITIKGT-------------TAYVPQQSWIQNGTIKDNILFG-T
MRP3 : 657 VAVVGPVGCGKSSLVSALLGEMEKLEGKVHMKGS-------------VAYVPQQAWIQNCTLQENVLFG-K
MRP4 : 441 LAVVGPVGAGKSSLLSAVLGELAPSHGLVSVHGR-------------IAYVSQQPWVFSGTLRSNILFG-K
MRP5 : 591 VGICGSVGSGKTSLISAILGQMTLLEGSIAISGT-------------FAYVAQQAWILNATLRDNILFG-K
MRP6 : 659 LAVVGPVGAGKSSLLSALLGELSKVEGFVSIEGA-------------VAYVPQEAWVQNTSVVENVCFG-Q
CFTR : 454 LAVAGSTGAGKTSLLMMIMGELEPSEGKIKHSGR-------------ISFCSQFSWIMPGTIKENIIFG-V
Pgp  : 420 VALVGNSGCGKSTTVQLLQRLYDPTEGVVSIDGQDIRTINVRYLREIIGVVSQEPVLFATTIAENIR RE
Walker A MRP subfamily short
deletion helix
MRP1 : QLEEPYYRSVIQACALLPDLEILPSGDRTEIGEKGVNLSGGQKQRVSLARAVYSNADIYLFDDPLSAVDA 800
MRP2 : EFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLDIYLLDDPLSAVDA 793
MRP3 : ALNPKRYQQTLEACALLADLEMLPGGDQTEIGEKGINLSGGQRQRVSLARAVYSDADIFLLDDPLSAVDS 783
MRP4 : KYEKERYEKVIKACALKKDLQLLEDGDLTVIGDRGTTLSGGQKARVNLARAVYQDADIYLLDDPLSAVDA 567
MRP5 : EYDEERYNSVLNSCCLRPDLAILPSSDLTEIGERGANLSGGQRQRISLARALYSDRSIYILDDPLSALDA 717
MRP6 : ELDPPWLERVLEACALQPDVDSFPEGIHTSIGEQGMNLSGGQKQRLSLARAVYRKAAVYLLDDPLAALDA 785
CFTR : SYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDV 580
Pgp  : NVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALDT 560
ABC signature Walker B
YG
α
Fig. 1. Alignment of the amino acid sequences of NBD1 in MRP1 and several ABC transporters closely related to MRP1. Amino acids sequences of
human MRP2, MRP3, MRP4, MRP5, MRP6, CFTR and Pgp were compared to MRP1. The Walker A and B sites, the 13 amino acids MRP
subfamily deletion, the ABC signature and the conserved short a helix are indicated by a light grey boxes. The studied phenylalanine residue (or
tyrosine in Pgp) is indicated by a dark grey box and a star (*).
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Research Laboratories and Department of Pharmacology and Toxi-
cology, Queens University, Kingston, Ontario K7L 3N6, Canada).
2.2. Cell culture
The wild-type and mutant overexpressing cells were stably transfec-
ted in HEK293 cells grown in DMEM supplemented with 10% fetal
bovine serum, 4 mM L-glutamine and 1% of a penicillin/streptomy-
cin/fungizone solution (Gibco BRL, Invitrogen).
2.3. Vector construction and site-directed mutagenesis
A sequence corresponding to a 6-polyhistidine tag was added by site-
directed mutagenesis at the 3 0 end of the MRP1 gene in the pRC/
CMV-MRP1 plasmid in order to purify the protein. Deletion of
Phe728 in MRP1 was generated using the QuikChange XLe site-direc-
ted mutagenesis kit (Stratagene, La Jolla, CA). The mutagenesis was
performed by PCR on the eucaryotic expression vector pRC/CMV-
MRP1 with the following mutagenic primer (\ represents the deleted
TTT codon): 5 0-CCG AGA AAA CAT CCT \ TGG ATG TCA
GCT GGA GG-3 0. The mutation and the integrity of the rest of the
MRP1 gene were veriﬁed by DNA sequencing (Eurogentec).
2.4. Transfections of mutant MRPDF728 expression vector in human
embryonic kidney cells (HEK293)
Wild-type pRC/CMV-MRP1 and mutant pRC/CMV-MRPDF728
expression vectors were transfected into human embryonic kidney cells
(HEK 293). Cells were seeded in a 6-wells plate, grown to 80% of the
conﬂuence and transfected with the corresponding plasmid using
DiC14 amidine, a cationic lipid designed by our team and protamine
sulfate, as an activator peptide [22,23]. A stable HEK 293 cell line
expressing MRPDF728 was generated by exposure to geneticin (0.5
lg/ml) for several months.
2.5. Determination of wild-type and mutant levels of expression
The relative levels of wild-type and mutants expression were deter-
mined by immunoblot and densitometry analysis. Brieﬂy, 5 · 105 cells
were lyzed into Sample Buﬀer, resolved on SDS–PAGE (7.5%) andelectrotransferred to nitrocellulose membrane. Afterwards, membrane
was blocked in PBS buﬀer containing 5% BSA and incubated over-
night with the mouse monoclonal primary antibody MRPm6 (dilution
1:4000). The membrane was washed and incubated with an anti-mouse
antibody conjugated to horseradish peroxydase (dilution 1:2000).
Immunoreactive proteins were visualized by chemiluminescence using
ECL Plus Western Blotting detection reagents.2.6. Fluorescence microscopy
Fluorescence microscopy was performed according to the protocol
of Zhang et al. [24]. MRP1 localization was determined using an Axio-
vert S100 TV (Zeiss) ﬂuorescence microscope (xenon lamp; kex and kem
are respectively 540 ± 25 and 605 ± 55 nm for propidium iodide and
respectively 480 ± 30 and 560 ± 80 nm for Alexa Fluor 488).
2.7. MTT cells viability test
Brieﬂy, cells were seeded in a 96 wells plate. The day after, various
concentrations of drug were added to the cells. After 72 h incubation,
drug and medium were removed and 100 ll of the MTT reagent (0.5
mg/ml) was added. After 3 h, the crystals of formazan produced were
solubilized by mixing with 100 ll DMSO. Absorbance was deter-
mined at 540 nm using an Elisa plate reader (Titertek Multiskan Plus
MK II).2.8. Puriﬁcation and reconstitution of MRPDF728
The MRPDF728-overexpressing cells HEK 293 were lyzed by soni-
cation and the nuclei and unlyzed cells were removed by centrifuga-
tion. The plasma membranes were puriﬁed on a sucrose gradient,
washed twice and pelletted by ultracentrifugation. The membrane pro-
teins were solubilized by an anionic detergent (DDM, n-dodecyl-b-D-
maltoside) and loaded on a Cobalt Histidine Bind Resin column
(Clontech). After the washing steps, the protein bound to the resin
thanks to its histidine tag was eluted by a Tris buﬀer containing 50
mM imidazole. Excess of salt was removed by centrifugation on
MicroSpin G-25 columns (Amersham Pharmacia Biotech). Reconsti-
tution of the puriﬁed protein into liposomes was performed as de-
scribed previously [25,35].
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Attenuated total reﬂection Fourier transform infrared spectroscopy
(ATR-FTIR) spectra were recorded at room temperature on a Bruker
IFS55 FTIR spectrophotometer equipped with a liquid nitrogen-
cooled mercury-cadmium-telluride (MCT) detector at a nominal reso-
lution of 2 cm1, and encoded every 1 cm1. The spectrophotometer
was continuously purged with air dried with a FTIR purge gas gener-
ator 75–62 Balston (Maidstone, England) at a ﬂow rate of 5.8 1/min.
The internal reﬂection element (ATR) is a germanium plate
(50 · 20 · 2 mm) with an aperture angle of 45, yielding 25 internal
reﬂections [26],
2.9.1. Sample preparation. The sample contained 20 lg of recon-
stituted MRP1. For the measurements carried out in the presence of
diﬀerent ligands, the molar protein to ligand ratio is 1/14 for DOX,
1/3 for GSH and 1/6 for ATP. Thin ﬁlms of oriented multilayers
were obtained by slowly evaporating the sample on one side of
the ATR plate under a stream of nitrogen [26]. The ATR plate
was then sealed in a universal sample holder (Harrick Scientiﬁc).
2.9.2. Secondary structure analysis. The sample on the ATR plate
was equilibrated with D2O-satured N2 for 16 h, at room temperature.
256 scans were averaged for each measurement. The determination of
the secondary structure was based on the shape of the Amide I band
(1600–1700 cm1), which is sensitive to the secondary structure [27].
The analysis was performed on the Amide I region of deuterated
samples because the H/D exchange allows diﬀerentiation of the a-
helical secondary structure from the random secondary structure
whose absorption band shifts from about 1655 cm1 to about 1642
cm1 [28]. A combination of Fourier self-deconvolution and a least
squares iterative curve ﬁtting was applied to narrow and to quantify
the area of the diﬀerent components of Amide I band between 1700
and 1600 cm1 [29]. To avoid the introduction of artifacts due to the
self-deconvolution procedure, the ﬁtting was performed on the non-
deconvoluted spectrum. The proportion of a particular structure
was computed as the sum of the area of all the ﬁtted Lorentzian
bands having their maximum in the frequency region where that
structure occurs divided by the total area of the Amide I. The fre-
quency limits for each structure were assigned according to theoreti-
cal [30] or experimental [31] data: 1662–1645 cm1, a-helix; 1689–
1682 and 1637–1613 cm1, b-sheet; 1644.5–1637 cm1, random;
1682–1662.5 cm1, b-turns.
2.9.3. H/D exchange kinetics. Films containing 20 lg of reconsti-
tuted MRP1 were formed on a germanium plate as described above.
Nitrogen was saturated with D2O by bubbling in a series of three vials
containing D2O. Before starting the deuteration, 10 spectra of the sam-
ple were recorded to test the stability of the measurements. At zero
time, the D2O-saturated N2 ﬂux, at a ﬂow rate of 100 ml/min, was con-
nected to the sample. For each kinetic time point, 24 scans were re-
corded and averaged at a resolution of 2 cm1. The signal from the
atmospheric water was subtracted as described by Goormaghtigh
et al. [32]. As previously described [30], deuteration of protein side-
chains induces modiﬁcations in the Amide I (1700–1600 cm1) and
Amide II (1600–1500 cm1) regions. Several parameters modulate their
contribution including ionization state of the carboxylic amino acids
and the fraction of deuterated and undeuterated amino acid side chains
for every spectrum of the kinetics. We used homemade software, which
can compute the contribution of the amino acid side-chains as a func-
tion of the extent of deuteration [33]. The area of Amide II, character-
istic of the d(N–H) vibration, was obtained by integration between
1596 and 1502 cm1. For each spectrum, the area of Amide II was di-
vided by the corresponding lipidic m(C‚O) area to take into account
small but signiﬁcant variations in the total intensity due to the presence
of D2O which induces swelling of the sample layer at the beginning of
the kinetics [28]. This ratio expressed in percentage was plotted versus
deuteration time. The value corresponding to 0% of deuteration is de-
ﬁned by the Amide II/lipid ratio before deuteration. The 100% value
corresponds to a zero absorption in the Amide II region, observed
for full deuteration of the protein.3. Results
Deletion of phenylalanine 508 in CFTR results in a loss
of expression of the membrane protein, which is retainedin the endoplasmic reticulum in an inactive form that is
rapidly degraded. In MRP1, the position of phenylalanine
728 (F728) is identical to that of F508 in CFTR with re-
spect to the Walker sites (Fig. 1). We expressed the
MRPDF728 mutant and investigated how DF728 mutation
aﬀects the cell assignment, drug transport activity and struc-
ture of MRP1.3.1. Expression and cellular localization of mutant MRPDF728
in stably transfected HEK293 cells
Site-directed mutagenesis was performed as described in Sec-
tion 2. The mutation and the integrity of the rest of the
MRPDF728 gene were veriﬁed by DNA sequencing (Eurogen-
tec, results not shown). The eucaryotic expression vector pRC/
CMV-MRPDF728 was used to stably transfect HEK293 cells.
After selection of cells resistant to geneticin, we isolated by
limiting cell dilution subpopulations of cells expressing
MRPDF728 at a level similar to the one obtained for MRP1
in HEK293 cells. Immunoblotting and densitometry analysis
demonstrated that the yield of MRPDF728 expression in
HEK 293 transfected cells is similar to MRP1 (Fig. 2). Indeed
the area of the second peak (peak 2) representing the density of
the MRPDF728 band in the immunoblot is about 97% of the
area of the ﬁrst one (peak 1) corresponding to the rate of
expression of WT MRP1.
The cellular localization of MRP1 and mutants was deter-
mined by ﬂuorescence microscopy on transfected HEK293
cells. Digitonin-permeabilized cells were incubated with a
mouse MRP1-speciﬁc primary monoclonal antibody MRPm6
which recognizes a linear epitope near the intracellular
COOH-terminus of the protein. The secondary mouse anti-
body Alexa Fluor 488 is visualized by the green ﬂuorescence.
Nuclei were coloured in red by propidium iodide. As shown
in Fig. 3, cells expressing wild-type (Fig. 3C) and mutants
(Fig. 3E) exhibited strong plasma membrane localization,
indicating that the DF728 mutation did not aﬀect the protein
traﬃcking.3.2. Cellular localization of mutant MRPDF728 in transiently
transfected HEK293 cells after GSH depletion in the
presence or the absence of doxorubicin
BSO is an inhibitor of GSH biosynthesis. In order to de-
scribe the cellular targeting of MRPDF728 in the absence of
intracellular GSH, HEK293 cells were incubated during 24 h
in 25 lM BSO before transfection. Under these conditions,
the intracellular GSH concentration level is reduced by about
90% (data not shown and [34]). Cells were transfected with
wild-type and mutant genes-containing expression vectors
and incubated again in 25 lM BSO for 48 h. Fluorescence
microscopy was performed on transfected and untransfected
HEK293 cells as described before. Interestingly, it appears that
after GSH depletion, the mutant is no longer routed to the
plasma membrane but is retained into the cytoplasm (Fig.
3D). In the same conditions, mutant in the presence of intracel-
lular GSH (Fig. 3E), in the presence of intracellular GSH and
doxorubicin (Fig. 3G) and wild-type protein in the absence
(Fig. 3B) or in the presence (Fig. 3C) of intracellular GSH were
correctly targeted to the plasma membrane. Incubation with
doxorubicin after GSH depletion does not restore the routing
to the plasma membrane (Fig. 3F).
Fig. 2. Western Blot and densitometry analysis on MRP1- and
MRFDF728-overexpressing cells. MRP1 (lane 1) and MRPDF728
(lane 2) were detected with monoclonal antibody MRPm6. The same
quantities of cell lysates were loaded on each lane.
Fig. 3. Fluorescence microscopy of HEK-MRP1 and HEK-
MRPDF728 cells after intracellular GSH depletion and/or doxorubicin
incubation. Nuclei are coloured in red by propidium iodide. Wild-type
and mutant MRP1 proteins are coloured in green by Alexa ﬂuor 488.
(A) Untransfected HEK293 cells; (B) HEK-MRP1 cells after GSH
depletion; (C) HEK-MRP1 cells without GSH depletion; (D) HEK-
MRPDF728 cells after GSH depletion; (E) HEK-MRPDF728 cells
without GSH depletion; (F) HEK-MRPDF728 cells after GSH
depletion and incubation with doxorubicin; (G) HEK-MRPDF728
cells without GSH depletion and after incubation with doxorubicin.
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and mutant MRPDF728 cells
MRP1 confers resistance to anticancer drugs by rejecting
them out of the cells and so reducing their intracellular accu-
mulation. Two antitumoral drugs, an anthracycline (Doxoru-
bicin, DOX) and a Vinca alcaloid (Vincristine, VCR) were
used to assess the resistance proﬁles of wild type and mutant
DF728 overexpressing HEK293 cells. Drug resistance was also
determined after BSO-mediated intracellular GSH depletion.
Drug resistance of wild-type and mutants overexpressing cells
was determined by a cell viability MTT-test following exposure
to increasing concentrations of drugs. Results clearly showed a
similar drug resistance in cells overexpressing the wild-type or
mutant. Indeed the vincristine IC50 values for MRP1 or
MRPDF728-overexpressing cells are 18.1 ± 2.1 and 22.6 ± 2.4
nM respectively versus 3.7 ± 0.5 nM for MRP1-not expressing
cells. The doxorubicin IC50 values were 91 ± 5, 93 ± 9 and
35 ± 5 nM, respectively. Accumulation of Fluo3 (which does
not need GSH for its transport) in MRPDF728 expressing cells
treated or not with BSO revealed that in the absence of BSO,cells excreted Fluo3 more eﬃciently than BSD-treated cells
(data not shown).
3.4. Comparison of wild-type MRP1 and correctly targeted
MRPDF728 mutant structure
A key point was to know whether MRPDF728 in the plasma
membrane is folded in a ‘‘wild-type’’ conﬁguration. Compari-
son of the structural characteristics of MRPDF728 and wild-
type MRP1 is a way to address this point. ATR-FTIR
spectroscopy has been proven to be an adequate tool to study
the structure of a protein in its lipid environment [26–29] even
if minimal amounts of protein material are available.
3.4.1. Puriﬁcation and reconstitution of MRPDF728 from
the plasma membrane. Brieﬂy, solubilized membranes pro-
teins were loaded on a Talon cobalt histidine bind resin. The
resin was washed twice with 10 volumes column of puriﬁca-
tion buﬀer containing successively 1 and 4 mM imidazole.
MRPDF728 was eluted with puriﬁcation buﬀer containing
high imidazole concentrations (50 mM) without any contam-
inant protein visible on the gel (Fig. 4, lane 3). This one-step
protocol provides us a highly puriﬁed MRPDF728. After con-
centration and dialysis of the protein sample, it was reconsti-
tuted into liposomes of asolectine as described previously
[25,35].
3.4.2. MRPDF728 secondary structure in the lipid bi-
layer. The secondary structure of MRPDF728 was deter-
mined by Fourier deconvolution and curve-ﬁtting analysis of
the amide I band of a deuterated sample as previously de-
scribed [29]. The proportions of diﬀerent secondary structures
Fig. 5. Infrared spectra in the 1800–1400 cm1 region of MRPDF728
reconstituted into lipids. Thin ﬁlms were obtained by slowly evapo-
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29 ± 3% b sheet for MRP1; 40 ± 2% a helix and 28 ± 1% b
sheet for MRPDF728). Both MRPDF728 and wild-type
MRP1 adopt a similar structure when inserted into the plasma
membrane.
3.4.3. Kinetics of deuteration of MRPDF728. At constant
pH and temperature, the rate of amide hydrogen exchange
by deuterium is related to the stability of the secondary struc-
tures and/or to the solvent accessibility of the NH amide
groups. Amide hydrogen exchange was followed by monitor-
ing the decrease of the amide n absorption peak of MRP1
(maximum at 1544 cm1) as a function of the time of exposure
to D2O-saturated N2 ﬂow (Fig. 5). The decreasing area of
amide II computed between 100% and 0% (see Section 2) is re-
ported in Fig. 6. 37% of the amide hydrogens of MRPDF728
remain unexchanged after 2 h of deuteration. One should have
in mind that this method is extremely sensitive to minor struc-
tural changes and has been used successfully to identify tran-
sient structural intermediates involved in ABC transporters
[25,35,45]. The fact that the kinetics of deuteration are identi-
cal in the limit of the error bars for both proteins demonstrates
that the two proteins adopt a similar tertiary structure (Fig. 6).
rating a sample containing 20 lg of MRPDF728 on an attenuated total
reﬂection element. Spectra were recorded as a function of the time (in
minutes) of exposure to D2O-saturated N2. Negative times refer to
spectra recorded before starting the deuteration procedure. Inset shows
the decrease in intensity of the amide II band during the H/D exchange
kinetics of MRPDF728.4. Discussion
A single mutation corresponding to the deletion of phenylal-
anine 508 in CFTR is responsible for over 70% of the cystic
ﬁbrosis (CF). This mutation aﬀects the folding of CFTR which
is retained into the endoplasmic reticulum in an immature and
inactive form that is rapidly degraded [3–6]. Phenylalanine 508
of CFTR is present in a sequence of 7–9 amino acids which has
a propensity to fold as a short a-helix [37,38]. This sequence is
located between the Walker A and B sites of NBD1. Studies on
short synthetic peptides showed that deletion of F508 from this
short a-helix in CFTR destabilizes the entke helix [38,39].
Other studies showed that this destabilization mediates anFig. 6. Evolution of the proportion of unexchanged amide bonds of
MRP1 and MRPDF728 computed between 100% and 0% as a function
of the deuteration time. MRP1 (d); MRPDF728 (m). The curves are
the means of three experiments.
Fig. 4. Puriﬁcation of MRPDF728 on cobalt-chelated aﬃnity resin.
Lane 1: high range molecular weight markers; lane 2: membrane
proteins; lane 3: elution of the mutant with 50 mM imidazole.inhibition of the entire NBD1 folding [40]. Misfolded
CFTRAF508 is no longer recognized or accepted by the cellu-
lar ‘‘quality control’’ mechanism.
An homologous phenylalanine residue is found at position
728 in MRP1. Oppositely to CFTRDF508, MRPDF728 is
150 F. Buyse et al. / FEBS Letters 578 (2004) 145–151correctly routed to the plasma membrane when expressed in
HEK293 cells. Cell multidrug resistance associated to the over-
expression of MRP1 is not aﬀected by the DF728 mutation.
The resistance to two cytotoxic substrates (DOX, VCR) is sim-
ilar for MRP1 and MRPDF728 overexpressing cells. Incuba-
tion of MRPDF728 overexpressing cells with doxorubicine
does not aﬀect the protein localization. However depletion of
intracellular GSH by addition of 25 lM BSO to the culture
medium leads to an incorrect protein targeting that is not re-
verted by addition of the MRP1 substrate doxorubicin. Indeed
after intracellular GSH depletion, the protein is not routed to
the plasma membrane and is retained into the cytoplasm.
Infrared spectroscopy on puriﬁed and reconstituted
MRPDF728 mutant demonstrated unambiguously that its sec-
ondary structure is similar to the one of MRP1 in the absence
of ligands. Recent studies have for the ﬁrst time demonstrated
that GSH binding strongly stabilizes MRP1 and protects it
from proteolysis, whereas drug binding renders the protein
more accessible. Indeed after 90 min incubation with trypsin,
MRP1 in the presence of GSH remains uncleaved [35]. Our
hypothesis is that GSH binds to the neo-synthesized protein
and stabilizes it in a conformation that is recognized by the
‘‘quality control’’ mechanism and correctly targeted to the
plasma membrane. If GSH is absent, the new protein would
be retained into the endoplasmic reticulum (ER) or others
cytosolic compartments. GSH may act as a speciﬁc endoge-
nous chaperone of MRP1, which allows the protein to be cor-
rectly folded and targeted. This speciﬁcity is plausible since
MRP1 presents speciﬁc GSH-binding sites and needs GSH
to co-transport many drugs. GSH binding sites have recently
been identiﬁed: one site is located in two cytosolic loops (the
loop between the transmembrane helices 5 and 6 and the loop
containing the NBD1) and an other one is composed by the
transmembrane helices 10, 11, 16 and 17 [44].
Similar rescuing processes have been observed for
CFTRDF508 when cells are grown at lower temperatures or
in the presence of glycerol [41,42] that acts as a chemical chap-
erone [43] and have also been reported for PgpAY490, a Pgp
mutant equivalent to MRPDF728 and CFTRDF508 [36]. This
tyrosine residue Y490 is located in the conserved short helix
mentioned above (Fig. 1). As in the case of MRPDF728 in
the absence of GSH and CFTRDF508, Pgp DY490 is not cor-
rectly routed to the plasma membrane. It is retained into the
cytoplasm in an inactive and defectively processed form. How-
ever cells incubation with cyclosporin A, a Pgp-substrate, re-
stores the right processing and targeting of the mutant which
becomes as active as the wild-type protein. ATR-FTIR struc-
tural characterization performed on Pgp in the presence of an-
other substrate (verapamil) showed a strong stabilization of
the protein [45]. This suggests that in contrast to MRP1, a
Pgp substrate stabilizes PgpDYa490 and allows it to be cor-
rectly routed. Cyclosporin A acts for PgpDY490 as a chemical
chaperone.
In conclusion, in the absence of intracellular GSH,
MRPDF728 is not correctly routed to the plasma membrane.
The presence of GSH strongly stabilizes the mutant and pro-
tects it from degradation. This stable conformation allows
the protein to be accepted by the cellular ‘‘quality control’’
mechanism, which targets it to the plasma membrane. GSH
is ﬁnally released and the protein recovers a conformation sim-
ilar to the wild-type as we veriﬁed by IR spectroscopy. These
data are in agreement with recent results obtained by our team,which demonstrated that GSH binding strongly stabilizes
MRP1 structure and signiﬁcantly enhances its protection
against proteolysis [35]. Our work could also suggest that in
cells expressing CFTRDF508, cytosolic GSH concentration is
not suﬃcient to allow a correct routing of the protein to the
plasma membrane.
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